Sept. 10, 2013
/PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, announced today that
, CEO, will present at the First Global Life Sciences Conference to be held on
September 16-17, 2013
. Mr. Riley is scheduled to present at
(Central European Summer Time)/
5:15 a.m. (Eastern Time)
Monday, September 16, 2013
at the Warsaw Stock Exchange.
A live webcast of Synthetic Biologics' presentation can be accessed by logging onto the internet at
. After the presentation, a replay will be archived and accessible for 30 days at the same website.
Mr. Riley, as well as Synthetic Biologics' CFO,
C. Evan Ballantyne
, will be available to participate in one-on-one meetings with conference attendees. To arrange a one-on-one meeting with Synthetic Biologics, please contact
or by phone +48 784 094 599.
WDM Capital, a prominent small cap investment bank in Central and
, is organizing the conference in partnership with the Warsaw Stock Exchange and Deloitte. For more information visit:
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE MKT: SYN) is a biotechnology company focused on the development of biologics for the prevention and treatment of serious infectious diseases. The Company is developing an oral enzyme for the prevention of
infections, and a series of monoclonal antibody therapies for the treatment of
infections. In addition, the Company is developing a drug candidate for the treatment of relapsing-remitting multiple sclerosis and cognitive dysfunction in multiple sclerosis. For more information, please visit Synthetic Biologics' website at
To download Synthetic Biologics' investor relations mobile device app, which allows users access to the Company's SEC documents, press releases and events, please click on the following links to download the IRapp on your
iPhone and iPad
Android mobile device
SOURCE Synthetic Biologics, Inc.